Composite Biomarker Panels

1 B1: Fecal Butyrate-Zonulin Composite Permeability Index (0.65)

2 B2: Colonocyte Energy Status Biomarker Panel (0.50)

3 B6: Systemic Butyrate-Bioavailability Monitoring (0.40)

4 B7: HIF-1α Target Gene Expression Panel (0.50)

5 Multi-Omics Approaches

Integrating multiple biomarker types:

Combining metabolomics, proteomics, transcriptomics
Machine learning for pattern recognition
May capture disease complexity better than single markers
Requires large, well-characterized cohorts

6 Machine Learning Applications

Computational approaches to biomarker discovery:

Random forests, neural networks for classification
Feature selection to identify most informative markers
Integration of clinical and molecular data
Cross-validation to prevent overfitting

7 Diagnostic Accuracy

Published multi-marker panels:

Some report \(>\) 90% sensitivity and specificity
Independent validation often shows lower performance
Need for prospective validation in diverse populations
Comparison to clinical diagnosis as gold standard problematic

8 Commercial Tests Available

Current commercial offerings:

Several proprietary tests marketed
Limited independent validation
Variable acceptance by clinicians and insurers
Ongoing development of improved panels